What is the appropriate dosing regimen for diltiazem?

Diltiazem Dosing

For acute rate control of supraventricular tachycardia (SVT) including atrial fibrillation with rapid ventricular response, administer diltiazem as a 0.25 mg/kg IV bolus over 2 minutes, followed by an infusion of 5-15 mg/h if needed. For chronic oral therapy in angina, start with 30 mg four times daily and titrate up to 180-360 mg/day in divided doses 1, 2.

Intravenous Dosing for Acute Rate Control

The ACC/AHA/HRS guidelines establish the standard approach 1:

• Initial bolus: 0.25 mg/kg IV over 2 minutes
• Repeat dosing: If inadequate response after 15 minutes, may give additional bolus
• Maintenance infusion: 5-10 mg/h, titrate up to 15 mg/h as needed

Important Dosing Nuance: Weight-Based vs. Fixed Dosing

While guidelines recommend weight-based dosing, recent evidence suggests lower doses may be equally effective with better safety profiles. Research shows that doses ≤0.2 mg/kg achieve similar rate control (70.5% success) compared to standard 0.25-0.3 mg/kg dosing (77.1% success), but with significantly lower hypotension rates (18% vs. 34.9%) 3. Another study found standard 10 mg fixed doses were noninferior to weight-based dosing for achieving therapeutic response 4.

Clinical approach: In patients at higher risk for hypotension (elderly, low body weight, baseline low blood pressure), consider starting with 10-15 mg fixed dose or 0.2 mg/kg rather than the full 0.25 mg/kg to minimize adverse events while maintaining efficacy.

Oral Dosing Regimens

For Angina (Immediate-Release)

2 specifies:

• Starting dose: 30 mg four times daily (before meals and bedtime)
• Titration: Increase gradually at 1-2 day intervals
• Target range: 180-360 mg/day in divided doses (3-4 times daily)
• Tablets may be swallowed whole, crushed, or chewed

For Hypertension (Extended-Release)

• Starting dose: 180-200 mg once daily for sustained-release formulations 5
• Maximum: 360 mg once daily
• Once-daily formulations provide 24-hour blood pressure control and improve compliance 6

Critical Contraindications and Precautions

Absolute contraindications 1:

• Second or third-degree AV block (without pacemaker)
• Sick sinus syndrome (without pacemaker)
• Decompensated systolic heart failure
• Hypotension
• Cardiogenic shock
• WPW syndrome with atrial fibrillation/flutter

Use with extreme caution in:

• Hepatic dysfunction: 69% increase in drug exposure 2
• First-degree heart block: Monitor closely, though diltiazem doesn't disproportionately worsen this 2
• Concurrent beta-blocker use: Limited safety data available 2

Pharmacokinetic Considerations

• Onset: IV effects within minutes; oral peaks at 2-4 hours 2
• Half-life: 3-4.5 hours 2
• Metabolism: Extensive hepatic first-pass (40% bioavailability) 2
• Therapeutic levels: 50-200 ng/mL 2
• Non-linear kinetics: Dose increases produce disproportionate increases in drug exposure 2

Common Pitfalls to Avoid

1. Overdosing in obese patients: Consider using ideal body weight for calculations, as actual body weight-based dosing in obese patients may lead to excessive doses and hypotension 7

2. Ignoring hepatic impairment: Titrate very cautiously in cirrhosis due to 69% increase in drug exposure 2

3. Missing WPW syndrome: Always verify rhythm is not pre-excited atrial fibrillation before administering, as diltiazem can precipitate ventricular fibrillation 1

4. Combining with other nodal blockers: Exercise extreme caution with concurrent beta-blockers or digoxin due to additive AV nodal effects 1